# US 2019/0314373 A1 · Aza-pyridone compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314373 A1
- Document ID: US20190314373A1
- Status: Published application
- Kind: A1
- Application number: 16/290,690
- Filed: 2019-03-01
- Published: 2019-10-17
- Earliest claimed: 2013-09-12
- Assignees: Alios BioPharma, Inc.
- Applicants: Alios BioPharma, Inc.
- Inventors: Robert Than HENDRICKS; Leonid BEIGELMAN; David Bernard SMITH; Antitsa Dimitrova STOYCHEVA
- Web page: https://patentgrep.com/patent/US20190314373A1

## CPC

- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/215: of carboxylic acids
- A61K 31/351: not condensed with another ring
- A61K 31/4965: Non-condensed pyrazines
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 38/212: {IFN-alpha}
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07B 59/002: {Heterocyclic compounds}
- C07D 487/04: Ortho-condensed systems
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection.

## Claims

### Claim 1

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) has the structure:
wherein:
is a single bond or double bond;
R1 is selected from the group consisting of hydrogen, an unsubstituted C1-4 alkyl, —C(═O)Y1, —C(═O)—O—Y1, —(CH2)—O—C(═O)—Y1, —(CH2)—O—C(═O)—O—Y1, —(CHCH3)—O—C(═O)—Y1 and —(CHCH3)—O—C(═O)—O—Y1;
R2 is selected from the group consisting of hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted heterocyclyl, an optionally substituted cycloalkyl(C1-6 alkyl), an optionally substituted aryl(C1-6 alkyl), an optionally substituted heteroaryl(C1-6 alkyl) and an optionally substituted heterocyclyl(C1-6 alkyl);
R3a and R3b are independently hydrogen or an optionally substituted C1-4 alkyl;
R4 and R5 are taken together with the carbon to which they are attached to form an optionally substituted tricyclic cycloalkenyl or an optionally substituted tricyclic heterocyclyl comprising one or two heteroatoms selected from the group consisting of N, O, and S;
R6 is selected from the group consisting of hydrogen, halogen, —CN, an optionally substituted C1-6 alkyl, an optionally substituted aryl, an optionally substituted heteroaryl, —CH2OH, —CH(Y2)(OH) and —C(O)Y2;
Y1 and Y2 are independently selected from the group consisting of an optionally substituted C1-6 alkyl, an optionally substituted C3-6 cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, a mono-substituted amino, a di-substituted amino and —C(R7)NHR8; and
R7 and R8 are independently hydrogen or an optionally substituted C1-4 alkyl.

### Claim at position 2

2-14. (canceled)

### Claim 15 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R4 and R5 are taken together with the carbon to which they are attached to form an optionally substituted tricyclic heterocyclyl comprising one or two heteroatoms selected from the group consisting of N, O, and S.

### Claim 16 (depends on 15)

The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein
R4 and R5 are taken together with the carbon to which they are attached to form an optionally substituted tricyclic heterocyclyl comprising two heteroatoms selected from the group consisting of N, O, and S.

### Claim 17 (depends on 15)

The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein the tricyclic heterocyclyl is substituted with one or more groups independently selected from fluoro, chloro, iodo and C1-4 alkyl.

### Claim 18 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is hydrogen.

### Claim 19 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is an optionally substituted C1-6 alkyl.

### Claim 20 (depends on 19)

The compound of claim 19, or a pharmaceutically acceptable salt thereof, wherein the optionally substituted C1-6 alkyl is substituted with substituent selected from the group consisting of halogen, haloalkyl, hydroxy and alkoxy.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen.

### Claim 23 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is an unsubstituted C1-4 alkyl.

### Claim at position 12

24-43. (canceled)

### Claim 44 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R6 is hydrogen.

### Claim 45 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R6 is halogen or —CN.

### Claim 46 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R6 is an optionally substituted C1-6 alkyl, an optionally substituted aryl or an optionally substituted heteroaryl.

### Claim 47

(canceled)

### Claim 48 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3a is hydrogen.

### Claim 49 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3a is an optionally substituted C1-4 alkyl.

### Claim 50 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3b is hydrogen.

### Claim 51 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3b is an optionally substituted C1-4 alkyl.

### Claim 52 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein is a single bond.

### Claim 53 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein is a double bond.

### Claim at position 23

54-57. (canceled)

### Claim 58 (depends on 1)

A pharmaceutical composition comprising an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

### Claim 59 (depends on 1)

A method for ameliorating or treating an orthomyxovirus infection comprising administering an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 60 (depends on 1)

A method for inhibiting replication of an orthomyxovirus virus comprising contacting a cell infected with the virus with an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 61 (depends on 1)

A method for contacting a cell infected with an orthomyxovirus virus comprising contacting a cell infected with the virus with an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 62 (depends on 1)

A method for ameliorating or treating an orthomyxovirus infection in combination with one or more additional agents comprising administering or contacting a cell with an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 63 (depends on 1)

A method for inhibiting endonuclease activity of an influenza endonuclease comprising contacting the active site of the endonuclease with an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 64 (depends on 59)

The method of claim 59, wherein the orthomyxovirus viral infection is influenza.

### Claim 65 (depends on 62)

The method of claim 62, wherein the orthomyxovirus viral infection is an influenza virus infection; and wherein the one or more additional agents is selected from the group consisting of a neuraminidase inhibitor, a M2 protein inhibitor, a polymerase inhibitor, a PB2 inhibitor, amantadine, rimantadine, zanamivir, oseltamivir, peramivir, laninamivir, laninamivir octanoate, favipiravir, fludase, ADS-8902, an immuno-modulator, beraprost, Neugene®, ribavirin, CAS Reg. No. 1422050-75-6, CAS Reg. No. 1259366-34-1 (VX-787), FluMist Quadrivalent® (MedImmune), Fluarix® Quadrivalent (GlaxoSmithKline), Fluzone® Quadrivalent (Sanofi Pasteur), Flucelvax® (Novartis) and FluBlok® (Protein Sciences).

### Claim 66

The method of 65, wherein the one or more additional agents is oseltamivir.

### Claim 67 (depends on 64)

The method of claim 64, wherein the influenza is influenza A.

### Claim 68 (depends on 64)

The method of claim 64, wherein the influenza is influenza B.

### Claim 69 (depends on 64)

The method of claim 64, wherein the influenza is influenza C.

### Claim 70 (depends on 64)

The method of claim 64, wherein the influenza is selected from the group consisting of H1N1, H3N2, H5N1 and H7N9.

### Claim 71 (depends on 1, 59)

The method of claim 59, wherein the compound of claim 1, or a pharmaceutically acceptable salt thereof, is effective against more than 1 subtype of influenza.

### Claim at position 38

72-84. (canceled)
